Company / Gross Margin
GYRE THERAPEUTICS, INC. Gross Margin History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
96.3%
FY2024
5-year range
95.3% / 96.3%
FY2022-FY2024
Trend
+1.1%
vs FY2023
Sector context
#1 of 28
Health Care
What the data says
Among 28 Health Care companies, GYRE THERAPEUTICS, INC. is in the top 4% for gross margin. Gross Margin remained relatively stable over the past 3 years, with values between 95.3% and 96.3%.
Based on SEC 10-K filings.
96.3% in FY2024. Ranks 1st among 28 companies in Health Care.
Remained stable around 96.3% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 4% in Health CareTop 4% of 28This company 96.3% Sector average 60.3%
▼
+59.8% above sector average
Key checks
Key Insights
- In FY2024, gross margin increased 1.1% year-over-year.
- Currently 36.0pp above the Health Care sector average.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 96.3% | +1.1% |
| FY2023 | 95.3% | -0.0% |
| FY2022 | 95.3% | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026